PDC 2019

2019

Asia Pneumococcal & Meningococcal Disease Conference
30–31 March Manila, Philippines

Current Options, Rational Decisions

Disclosure

This conference is sponsored by Pfizer Vaccines and most speakers or their institutions have received an honorarium for their time and input into the content
of their abstracts and presentations.

Disclaimer

The content contained in this meeting abstract book represents the opinions and experiences of the respective presenters only and does not necessarily
represent the views or recommendations of Pfizer. For specific information regarding therapeutic agents, including Pfizer products, please refer to the
approved prescribing information in your country.

2019

Asia Pneumococcal & Meningococcal Disease Conference
30–31 March Manila, Philippines

WELCOME MESSAGE

Dear Doctor,
Welcome to Manila for the annual Asia Pneumococcal and Meningococcal Disease Conference (PDC)
to be held on 30–31 March 2019. The PDC provides a platform for scientific exchange and sharing of
experience for experts throughout the region.

The theme this year is Current Options, Rational Decisions. The first day’s sessions are

on pneumococcal and meningococcal disease in pediatrics, and on day two on adult pneumococcal
disease.
The esteemed international and regional faculty will provide updates on epidemiology and burden
of pneumococcal and meningococcal disease globally and in Asia, and discuss currently available
options for, and their impact on, disease prevention. This, together with the latest on international
recommendations and local vaccination policies, will inform decision-making processes for patients
throughout Asia.
The sessions will feature live voting questions, and there will be ample opportunity for discussion and
interaction with the faculty and your peers from around the region.
Thank you once again for taking the time out of your schedules to attend the PDC, and we hope that
you enjoy your time in the vibrant city of Manila.

Yours sincerely,

Adriano Arguedas Mohs, MD Amgad Gamil, MD, MBA

Vaccines Scientific Affairs Medical Lead for Asia Emerging Markets, Regional Medical Lead Africa,
Pfizer Inc. Middle East (AfME) & Asia Regions, Vaccines
Pfizer Inc.

1

AGENDA – Day 1 • PDC

Saturday, 30 March 2019

Time Topic Speaker/Chairperson
08:00–08:15 Welcome remarks and meeting objectives Amgad Gamil

Session 1: Pneumococcal Disease in Pediatrics: Global Perspectives Jaime Santos
Ron Dagan
08:15–08:55 PCVs eighteen years after introduction in children: Did we live up to Eun Hwa Choi
our expectations? Stephen Pelton

08:55–09:35 Changes in pneumococcal serotype distribution following the Stephen Pelton
introduction of pneumococcal vaccination Ron Dagan
All speakers of Session 1
09:35–10:15 Nasopharyngeal colonization with Streptococcus pneumoniae:
Mechanics of surveillance and lessons learned

10:15–10:40 Coffee Break

10:40–11:10 Pneumococcal nasopharyngeal ecology and herd effect of
pneumococcal conjugate vaccines

11:10–11:40 Why is pneumococcal conjugated vaccine so different from other
vaccines?

11:40–12:20 Panel discussion

12:20–13:15 Lunch

Session 2: Pneumococcal Disease in Pediatrics: Regional Perspectives Ron Dagan

13:15–13:35 Current epidemiology and serotype distribution of pneumococcal Chun-Yi Lu
infections in Taiwan five years after a successful implementation of
PCV13 in the National Immunization Program

13:35–13:55 Epidemiology of pediatric community-acquired pneumonia in Naruhiko Ishiwada
Japan following the introduction of PCV7 and PCV13 in the National
Immunization Program in Japan

13:55–14:15 Improving PCV13 access in the Philippines through the Expanded Anna Ong-Lim
Program on Immunization

14:15–14:35 Community-acquired pneumonia in children in India: How PCV13 Srinivas G. Kasi
introduction in the National Immunization Program can benefit Indian
children

14:35–15:15 Panel discussion All speakers of Session 2

15:15–15:35 Coffee Break

Session 3: Meningococcal Disease Among Risk Groups Stephen Pelton

15:35–16:05 Epidemiology and risk of meningococcal disease: Global perspective Marco Aurélio Sáfadi

16:05–16:35 Scientific evidence and global recommendation for vaccination of Federico Martinón-Torres
children against meningococcus

16:35–16:55 Mass gatherings: Expanding vaccination strategies beyond Helmy Haja Mydin
meningococcal vaccination
16:55–17:25 Panel discussion All speakers of Session 3
17:25–17:30 Closing of Day 1 Amgad Gamil

2

AGENDA – Day 2 • PDC

Sunday, 31 March 2019

Time Topic Speaker/Chairperson
Adriano Arguedas Mohs
08:30–08:45 Recap of Day 1 and introduction to Day 2 Amgad Gamil
Helen Oh and
08:45–08:55 Objectives of Day 2 Julio Ramirez
Charles Feldman
Session 4: Pneumococcal Disease and Current Recommendations among Krzysztof Trzciński
Adults
Julio Ramirez
08:55–09:25 Global pneumococcal disease burden in adults
Charles Feldman
09:25–09:55 Pneumococcal upper respiratory tract colonization in adults: Latest Margaret Ip
update Helen Oh
Kuang-Yao Yang
09:55–10:25 Evaluation of real-world effectiveness of pneumococcal vaccination All speakers of Session 4
among adults Amgad Gamil

10:25–10:45 Q&A

10:45–11:00 Break

11:00–11:30 International recommendations for adult pneumococcal vaccination

11:30–11:45 Vaccination policy on adult pneumococcal diseases in Hong Kong

11:45–12:00 Adult pneumococcal disease in Singapore: Vaccination policy

12:00–12:15 Adult pneumococcal disease in Taiwan: Vaccination Policy

12:15–12:55 Panel discussion

12:55–13:00 Closing remarks

13:00 Lunch

Product indications and prescribing information may differ in each country. Please use products in accordance with the approved indication(s) and
prescribing information in your country.

3

FACULTY BIOGRAPHIES

Adriano Arguedas Mohs Pfizer

Adriano Arguedas Mohs is a Costa Rican citizen who was born in Brazil and is a Pediatric Infectious
Diseases Specialist. Dr Arguedas Mohs completed his residency in Pediatrics at the University of
Costa Rica (1988) and a Fellowship in Pediatric Infectious Diseases at the University of California,
Irvine (1991).
Currently resides in Collegeville, PA, USA and is the Scientific Affairs Lead for Emerging Markets in
Asia at Pfizer Inc.; he is also a Senior Lecturer in the Faculty of Medicine, Universidad de Ciéncias
Médicas in San José, Costa Rica. He has been a clinical instructor at the University of California, Irvine
and the University of Costa Rica and member of the Ethics Committee and of the Pharmacotherapy
Committee of the National Children’s Hospital of Costa Rica.
From 1992–2000 he served in various positions in the National Children’s Hospital of Costa Rica:
1991–1993: Attending Physician at the Department of Infectious Diseases; 1993–1998 Clinical Chief at
Medicine 1 Service; 1998–2000 Chief of the Emergency and Outpatient Department and Member of
the Hospital Technical Council. From 2001–2003 he was Head of the Division of Pediatric Research at
Neeman - ICIC and from 2003 to 2012 Founder and Director of the Instituto de Atención Pediátrica.
Dr Arguedas Mohs has a total of 120 publications in peer-reviewed journals, contributed in 15 chapters
for various medical textbooks, presented 150 papers at scientific conferences and given 250 lectures
at scientific meetings. He belongs to several global scientific committees and his current research
area focuses on disease prevention by new vaccines. He was awarded the Merle Carson Lectures
(Los Angeles, California, 1991) for the best research presentation in Southern California and twice
the prize awarded for scientific work (second place) for the Latin American Society of Pediatric
Infectious Disease Clinic (San José, Costa Rica [2007] and Guayaquil-Ecuador [2009]).

Eun Hwa Choi Korea

Eun Hwa Choi, MD, PhD, is a Professor of Pediatric Infectious Diseases in the Department of Pediatrics
at Seoul National University College of Medicine in Seoul, Korea.
Dr Choi earned her medical degree from Seoul National University in 1990. She completed a residency
in pediatrics and a clinical fellowship in pediatric infectious diseases at Seoul National University
Hospital. She then completed a 4-year research fellowship at the Immunocompromised Host Section
of the National Institutes of Health’s National Cancer Institute in Bethesda, Maryland, from 1999-2003.
In 2013, she conducted research on pneumococcal vaccine at the Division of Infectious Diseases of
Children’s Hospital Boston, Massachusetts.
Dr Choi’s research interests are focused on respiratory infections, particularly on the respiratory
virus and mycoplasma in children. Her research has been published in a number of peer-reviewed
journals, including Clinical Infectious Diseases, Journal of Infectious Diseases and Journal of Clinical
Microbiology.
Dr Choi currently serves the Korean Centers for Disease Control as a member of the Expert
Committee of Immunization Practice. She is also a chair of the Korean Pediatric Society’s Committee
on Infectious Disease.

4

FACULTY BIOGRAPHIES

Ron Dagan Israel

Ron Dagan is Distinguished Professor of Pediatrics and Infectious Diseases at the Ben-Gurion
University of the Negev, Beer-Sheva. He founded the Pediatric Infectious Disease Unit at the
Department of Pediatrics, Soroka University Medical Center, Beer-Sheva, Israel, and served as its
director from 1987 to June 2014. His previous appointments include Adjunct Associate Professor of
Pediatrics at the University of Rochester, New York, USA, from 1993 to 1998, in addition to Advisor for
Infectious Diseases at the Israeli Ministry of Health. Professor Dagan obtained his MD degree in 1974
from the Hadassah Medical School of the Hebrew University, Jerusalem, Israel. In 1982, he embarked
on a 3-year Fellowship in pediatric infectious diseases at the University of Rochester, Rochester, NY.
A member of several national and international advisory committees and medical and scientific
associations, Professor Dagan was the Chairman of the Advisory Committee for Infectious Diseases
of the Israeli Society of Pediatrics from 1992 to 1997 and has served on the National Advisory
Committee on Infectious Diseases and Immunization since 1991. He is also a Founding Member of
the World Society of Pediatric Infectious Diseases (WSPID) and a Fellow of the Infectious Diseases
Society of America (IDSA). He served as a member of the Executive Committee of the International
Society of Infectious Disease (ISID) from 2010 to 2016. Professor Dagan has been involved in the
World Health Organization (WHO) Working Group on Pneumococcal Nasopharyngeal Carriage and
the WHO Pneumonia Radiology Working Group. He served as President of the European Society
for Paediatric Infectious Diseases (ESPID) from 2004 to 2006, as President of the World Society for
Pediatric Infectious Diseases (WSPID) from 2006 through 2009 and as Chair of the Board of the
International Symposia on Pneumococcus and Pneumococcal Diseases (ISPPD) from 2010 to mid-
2016.
Professor Dagan serves on the editorial board of several peer-reviewed journals, including Pediatric
Infectious Disease Journal, Infection, Human Vaccines, Journal of Infectious Diseases, Vaccine and
International Journal of Infectious Diseases. He is a recipient of many grants and awards. During his
professional career, he has contributed over 500 original articles, reviews and book chapters, and
has presented more than 500 papers at national and international scientific meetings. Professor
Dagan has earned international recognition for his research, which has focused largely on the
development on vaccine preventable diseases, with particular emphasis on pneumococcal vaccines;
the understanding of hepatitis A epidemiology and introduction of hepatitis A vaccines; the
epidemiology of respiratory infections in children; clinical aspects of vaccination against antibiotic-
resistant pneumococci; the pathology of otitis media, role of resistant organisms in otitis media and
prediction of bacteriological response to various antibiotics; and the epidemiology and prevention
of enteric and invasive infections in young children.

5

FACULTY BIOGRAPHIES

6

FACULTY BIOGRAPHIES

7

FACULTY BIOGRAPHIES

8

FACULTY BIOGRAPHIES

9

FACULTY BIOGRAPHIES

10

FACULTY BIOGRAPHIES

11

FACULTY BIOGRAPHIES

12

FACULTY BIOGRAPHIES

13

ABSTRACTS: SESSION 1

14

ABSTRACTS: SESSION 1

15

ABSTRACTS: SESSION 1 & 2

16

ABSTRACTS: SESSION 2

17

ABSTRACTS: SESSION 2 & 3

18

ABSTRACTS: SESSION 3

19

ABSTRACTS: SESSION 4

20

ABSTRACTS: SESSION 4

21

ABSTRACTS: SESSION 4

22

ABSTRACTS: SESSION 4

23

Philippines Prevenar 13® Abbreviated Prescribing Information

Pneumococcal Conjugate Vaccine, 13-Valent

Prevenar 13® Suspension for Intramuscular (IM) Injection Pre-filled syringe

APPROVED INDICATIONS Decreased appetite, irritability, drowsiness/increased
Active immunization for the prevention of invasive sleep, restless sleep/decreased sleep, diarrhea, vomiting,
disease, pneumonia and acute otitis media caused by rash, fever, any vaccination-site erythema, induration/
Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, swelling or pain/tenderness, vaccination-site erythema or
7F, 9V, 14, 18C, 19A, 19F and 23F in infants, children and induration/swelling 2.5 cm – 7.0 cm (after toddler dose
adolescents. and in older children [age 2 to 5 years])

For adults aged 18 years and older, Pneumococcal Children and adolescents aged 5 to 17 years
Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar 13) Decreased appetite, irritability, drowsiness/increased
is indicated for the prevention of pneumococcal disease sleep, restless sleep/decreased sleep, headaches,
(including pneumonia and invasive disease) caused by diarrhea, vomiting, rash, urticaria or urticaria-like rash,
Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, fever, any vaccination-site erythema, induration/swelling
9V, 14, 18C, 19A, 19F and 23F. or pain/tenderness, vaccination-site tenderness (including
DOSAGE AND METHOD OF ADMINISTRATION impaired movement)
Pneumococcal Conjugate Vaccine, 13-Valent Adults aged 18 years and older
(adsorbed) (Prevenar 13) schedule for Infants and Decreased appetite, headaches, diarrhea, vomiting, rash,
Toddlers: generalized new/aggravated joint pain; generalized new/
aggravated muscle pain, chills, fatigue, vaccination-
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar 13) site erythema, vaccination-site induration/swelling,
Routine Vaccination Schedule for Infants and Toddlers vaccination-site pain/tenderness, limitation of arm
movement, fever
Dose Dose 1*† Dose 2† Dose 3† Dose 4‡

Age at Dose 2 months 4 months 6 months 12-15 months

* Dose 1 may be given as early as 6 weeks of age. DRUG INTERACTION
† The recommended dosing interval is 4 - 8 weeks. Different injectable vaccines should always be given at
‡ T he fourth dose should be administered at approximately 12-15 months of age, and at different vaccination-sites.
Infants and children aged 6 weeks to 5 years
least 2 months after the third dose. Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
(Prevenar 13) can be given with any of the following
Pneumococcal Conjugate Vaccine, 13-Valent vaccine antigens, either as monovalent or combination
(adsorbed) (Prevenar 13) schedule for children 24 vaccines: diphtheria, tetanus, acellular or whole-cell
months to 17 years of age: pertussis, Haemophilus influenzae type b, inactivated
Children 24 months to 5 years of age and children 6 poliomyelitis, hepatitis A, hepatitis B, meningococcal
years to 17 years of age may receive a single dose of serogroup C, measles, mumps, rubella, varicella, and
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) rotavirus.
(Prevenar 13) whether or not they have been previously Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
vaccinated with 1 or more dose of Pneumococcal 7-valent (Prevenar 13) can also be given concomitantly between
conjugate vaccine. If pneumococcal 7-valent conjugate 12-23 months of age with the tetanus toxoid conjugated
vaccine was previously administered, then at least 8 meningococcal polysaccharide serogroups A, C, W and Y
weeks should elapse before receiving Pneumococcal vaccine.
Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar 13). Children and adolescents 6 to 17 years of age
In children and adolescents, there are no data on the
Adults aged 18 years and older: concomitant administration of Pneumococcal Conjugate
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) Vaccine, 13-Valent (adsorbed) (Prevenar 13) with human
(Prevenar 13) is to be administered as a single dose papillomavirus vaccine (HPV), meningococcal protein
to adults 18 years and older including those previously conjugate vaccine (MCV4), or tetanus, diphtheria and
vaccinated with a pneumococcal polysaccharide vaccine. accellar pertussis vaccine (Tdap).
Adults 18 to 49 years of age
CONTRAINDICATIONS No data are currently available regarding concomitant use
Hypersensitivity to any component of the vaccine, with other vaccines.
including diphtheria toxoid.
Adults 50 years and older
PRECAUTIONS Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed)
Safety and immunogenicity data on Pneumococcal (Prevenar 13) can be administered concomitantly with
Conjugate Vaccine, 13-Valent (adsorbed) (Prevenar trivalent or quadrivalent inactivated influenza vaccine
13) are not available for individuals in specific (TIV or QIV)
immunocompromised groups (e.g., malignancy, or For full product information see product leaflet.
nephrotic syndrome) and vaccination should be ALPD Ver. No.: 9.0
considered on an individual basis. Reference: LPD Revision No.: 9.0 dated 29 November 2017

UNDESIRABLE EFFECTS
Infants and children aged 6 weeks to 5 years

24

Philippines Nimenrix Abbreviated Prescribing Information

Meningococcal polysaccharide serogroups A, C, W-135 and
Y conjugate vaccine

Nimenrix 5 mcg Lyophilized Powder for Solution for Injection (IM)v

THERAPEUTIC INDICATION/S. This vaccine should be given with caution to individuals
Nimenrix is indicated for active immunisation of with thrombocytopenia or any coagulation disorder
individuals from the age of 6 weeks against invasive since bleeding may occur following an intramuscular
meningococcal diseases caused by Neisseria administration to these subjects.
meningitidis serogroup A, C, W-135 and Y. Nimenrix will only confer protection against Neisseria
meningitidis serogroup A, C, W-135 and Y. The vaccine
DOSAGE AND METHOD OF ADMINISTRATION. will not protect against any other Neisseria meningitidis
This product should be used in accordance with serogroups.
available meningococcal vaccine recommendations. Nimenrix does not substitute for tetanus immunisation.
Infants from 6 to 12 weeks of age: Giving Nimenrix with or one month before a TT-containing
The recommended immunisation series consists of three vaccine in the second year of life does not impair the
doses, each of 0.5 ml. The primary infant series consists response to TT or significantly affect safety. No data are
of two doses, with the first dose given from 6 weeks of available beyond the age of 2 years.
age and with an interval of 2 months between doses. The DRUG INTERACTIONS.
third (booster) dose is recommended at 12 months of age. In infants, Nimenrix can be given concomitantly with
Children from 12 months of age, adolescents and adults: combined DTaP-HBV-IPV/Hib vaccines and with 10-valent
A single 0.5 ml dose should be administered. pneumococcal conjugate vaccine.
A second dose of Nimenrix may be considered appropriate
for some individuals. From age 1 year and above, Nimenrix can be given
Previously vaccinated children from 12 months of age, concomitantly with any of the following vaccines: hepatitis
adolescents and adults: A (HAV) and hepatitis B (HBV) vaccines, measles - mumps -
Nimenrix may be given as a booster dose in individuals rubella (MMR) vaccine, measles - mumps - rubella - varicella
who have previously received primary vaccination with (MMRV) vaccine, 10-valent pneumococcal conjugate
a conjugated or plain polysaccharide meningococcal vaccine or unadjuvanted seasonal influenza vaccine.
vaccine. In the second year of life, Nimenrix can also be given
Method of administration concomitantly with combined diphtheria - tetanus -
Immunisation should be carried out by intramuscular acellular pertussis (DTaP) vaccines, including combination
injection only. DTaP vaccines with hepatitis B, inactivated poliovirus or
In infants, the recommended injection site is the Haemophilus influenzae type b (HBV, IPV or Hib) such as
anterolateral aspect of the thigh. In individuals from 1 year DTaP-HBV-IPV/Hib vaccine, and 13-valent pneumococcal
of age, the recommended injection site is the anterolateral conjugate vaccine.
aspect of the thigh or the deltoid muscle. Whenever possible, Nimenrix and a TT containing vaccine,
CONTRAINDICATIONS. such as DTaP-HBV-IPV/Hib vaccine, should be co-
Hypersensitivity to the active substances of this administered or Nimenrix should be administered at least
vaccine or to any of the following excipients: Sucrose, one month before the TT containing vaccine.
Trometamol, and Sodium chloride. If Meningococcal polysaccharide serogroups A, C, W-135 and
Y conjugate vaccine (Nimenrix) is to be co-administered,
SPECIAL WARNINGS AND PRECAUTIONS FOR the vaccines should always be administered at different
USE. injection site.
Meningococcal polysaccharide serogroups A, C, W-135 It may be expected that in patients receiving
and Y conjugate vaccine (Nimenrix) should under immunosuppressive treatment an adequate response may
no circumstances be administered intravascularly, not be elicited.
intradermally or subcutaneously. UNDESIRABLE EFFECTS.
Vaccination with this product should be postponed in Pain, redness, swelling, irritability, drowsiness, loss
subjects suffering from an acute severe febrile illness. The of appetite, fever, headache, fatigue, gastrointestinal
presence of a minor infection, such as a cold, should not symptoms and fever.
result in the deferral of vaccination.

Syncope (fainting) can occur following, or even before, For full product information see product leaflet.
any vaccination especially in adolescents as a psychogenic ALPD Ver. no: 2.0
response to the needle injection. Reference: LPD Rev 2.0 dated 28 Nov 2017

For Healthcare Professionals Only. Full Prescribing Information is available upon request.
Product indications and prescribing information may differ in each country.
Please use products in accordance with the approved indication(s) and prescribing information in your country.

25

2019

Asia Pneumococcal & Meningococcal Disease Conference
30–31 March Manila, Philippines

Pfizer, Inc.
18/F - 20/F 8 Rockwell Building,
Hidalgo Drive, Rockwell Center, Poblacion, Makati City
March 2019
xx-xxx-xxx-xxxx